Author

Frank Hartmann

Observed names: F HARTMANN, F Hartmann, F. H. Hartmann, F. HARTMANN, F. Hartmann, F., Hartmann

Observed institutions: National Institutes of Health, University of Cologne, Johannes Gutenberg University Mainz, University of Münster, University of Würzburg, University Hospital Bonn, Peter MacCallum Cancer Centre, Medizinische Hochschule Hannover, Krankenhaus der Barmherzigen Brüder Trier, Universitätsklinikum Erlangen, Düsseldorf University Hospital, University Medical Center of the Johannes Gutenberg University Mainz, Universitätsklinikum des Saarlandes, University Medical Center Hamburg-Eppendorf, Klinikum Oldenburg, University Hospital Schleswig-Holstein, Universitätsmedizin Göttingen, Essen University Hospital, Diakonie Deutschland, Klinikum Lippe, St. Vincenz-Krankenhaus Limburg, National Cancer Institute, Gemeinschaftsklinikum Mittelrhein, University Hospital Ulm, Helios Hospital Berlin-Buch, Servier (Germany), Klinikum Chemnitz, Heinrich Heine University Düsseldorf, University of Rostock, Technical University of Munich, Charité – Universitätsmedizin Berlin, University of Tübingen, Ludwig-Maximilians-Universität München, Saarland University

ORCID: 0000-0002-3677-5196

Observed ORCID: 0000-0002-3677-5196

OpenAlex ID: A5102896495

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)

2006 · R. Forstpointner, M. Unterhalt, et al. · Blood · 469

PDF

Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal Cancer

2003 · R.-D. Hofheinz, S.-E. al-Batran, et al. · Oncology Research and Treatment · 387

Classification of Osteoporotic Thoracolumbar Spine Fractures: Recommendations of the Spine Section of the German Society for Orthopaedics and Trauma (DGOU)

2018 · Klaus John Schnake, Thomas R. Blattert, et al. · Global Spine Journal · 262

Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A

2010 · Richard F. Schlenk, Konstanze Döhner, et al. · Journal of Clinical Oncology · 229

PDF

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B

2008 · R. F. Schlenk, K. Dohner, et al. · Haematologica · 214

PDF

Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia

2004 · R F Schlenk, S Fröhling, et al. · Leukemia · 170

Treatment of Refractory Hodgkin's Disease With an Anti-CD16/CD30 Bispecific Antibody

1997 · Frank Hartmann, Christoph Renner, et al. · Blood · 152

Intralesional interferon-alpha therapy in advanced malignant melanoma

1988 · Peter Von Wussow, Berthold Block, et al. · Cancer · 151

Nonsurgical and Surgical Management of Osteoporotic Vertebral Body Fractures: Recommendations of the Spine Section of the German Society for Orthopaedics and Trauma (DGOU)

2018 · Thomas R. Blattert, Klaus J. Schnake, et al. · Global Spine Journal · 147

Salvage Treatment With Paclitaxel, Ifosfamide, and Cisplatin Plus High-Dose Carboplatin, Etoposide, and Thiotepa Followed by Autologous Stem-Cell Rescue in Patients With Relapsed or Refractory Germ Cell Cancer

2001 · O. Rick, C. Bokemeyer, et al. · Journal of Clinical Oncology · 140

Biomechanical properties of human intervertebral discs subjected to axial dynamic compression—Influence of age and degeneration

1986 · W. Koeller, S. Muehlhaus, et al. · Journal of Biomechanics · 125

Risk-adapted postremission therapy in acute myeloid leukemia: results of the german multicenter AML HD93 treatment trial

2003 · R F Schlenk, A Benner, et al. · Leukemia · 119

Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines.

2001 · F Hartmann, C Renner, et al. · PubMed · 99

High-risk additional chromosomal abnormalities at low blast counts herald death by CML

2020 · Rüdiger Hehlmann, Astghik Voskanyan, et al. · Leukemia · 93

PDF

Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.

1997 · E Horak, F Hartmann, et al. · PubMed · 86

Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide-conjugated monoclonal antibody 212Bi-anti-Tac.

1994 · F Hartmann, E M Horak, et al. · PubMed · 70

Biomechanical Properties of Human Intervertebral Discs Subjected to Axial Dynamic Compression

1984 · W KOELLER, W MEIER, et al. · Spine · 67

Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

2017 · M A Hoechstetter, R Busch, et al. · Leukemia · 66

Kyphoplasty as an alternative treatment of traumatic thoracolumbar burst fractures Magerl type A3

2010 · Frank Hartmann, Erol Gercek, et al. · Injury · 64

Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody.

1990 · U Sahin, F Hartmann, et al. · PubMed · 61

The anatomy of the proximal radius: implications on fracture implant design

2012 · Sebastian Kuhn, Klaus J. Burkhart, et al. · Journal of Shoulder and Elbow Surgery · 46

Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced HER-2/NEU activation, receptor expression and proliferation of HER-2-positive malignant cell lines

1997 · Frank Hartmann, Eva M. Horak, et al. · International Journal of Cancer · 46

High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia

2005 · R F Schlenk, U Germing, et al. · Leukemia · 45

Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group

2020 · Manuela A. Hoechstetter, Raymonde Busch, et al. · Leukemia · 44

Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia

2011 · C. Zwick, F. Hartmann, et al. · Annals of Oncology · 44

Works count: 107

Citation count: 4,326

H-index: 32

I10-index: 60